ArticleBiomacromolecules2026
PET-Trackable Carborane-Conjugated Star-Shaped Poly(2-Oxazoline) Scaffold with High Boron Payload and Improved Aqueous Solubility for Potential Application in Boron Neutron Capture Therapy.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Boron neutron capture therapy (BNCT) requires high, tumor-selective boron delivery, yet carboranes, boron-rich BNCT building blocks, often suffer from poor aqueous solubility and suboptimal in vivo behavior despite exceptional boron density and stability. We report a modular star-shaped poly(2-oxazoline) (POx) scaffold that carries a high carborane payload and can be followed by positron emission tomography (PET). An alkyne-bearing POx was conjugated with azidopropyl meta-carborane, yielding PBMM-mCB20-EIP that remained highly water-soluble (225 g/L, ∼26 g/L of boron, 20 carboranes/star). PBMM-mCB20-EIP exhibited good cytocompatibility in CAL 27 and FaDu head-and-neck cancer cells and showed higher cell-associated boron concentration than the clinical agent sodium borocaptate. A DOTA-modified analogue was prepared and radiolabeled with gallium-68 for PET imaging. In healthy mice, gallium-68-labeled DOTA-PBMM-mCB20 revealed substantial blood-pool activity (17%ID/g) at 90 min, predominant renal clearance, and low background uptake, providing a baseline for further macromolecular engineering of this carrier and irradiation-timing optimization in tumor models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.